PDE5A and cancer: PDE5 is part of the NO-sGC-cGMP-PDE5 signaling pathway (Bajraktari et al., 2017; Gur et al., 2020), and its inhibition has been associated with potentiating cancer therapy (Muniyan et al., 2020), counteracting diabetic heart kinetics (Pofi et al., 2022), ameliorating heart failure through cGMP-dependent protein kinase (PKG) activation (Zhu et al., 2022), and supporting increased blood perfusion oxygenation of the vasculature (Giuliano et al., 2013).